Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer

Vaccine

Volumn 30, Issue 2, 2012, Pages 189-194

  Zhu, Daming ^a   Huang, Shuhui ^a   McClellan, Holly ^a   Dai, Weili ^a   Syed, Najam R ^a   Gebregeorgis, Elizabeth ^a   Mullen, Gregory E D ^a   Long, Carole ^a   Martin, Laura B ^a   Narum, David ^a   Duffy, Patrick ^a   Miller, Louis H ^a   Saul, Allan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Alhydrogel; AMA1; Cetylpyridinium chloride; Extraction; SDS

Indexed keywords

ALUMINUM HYDROXIDE; AMA1 3D7 VACCINE; AMA1 FVO VACCINE; ANTIGEN; APICAL MEMBRANE ANTIGEN 1; APICAL MEMBRANE ANTIGEN 1 C1 VACCINE; BUFFER; CETYLPYRIDINIUM SALT; CITRIC ACID; DODECYL SULFATE SODIUM; MALARIA VACCINE; PHOSPHATE; SILVER; SURFACTANT; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANTIGEN EXTRACTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG ISOLATION; DRUG MANUFACTURE; DRUG POTENCY; EXTRACTION; FEMALE; HYDROGEL; MOUSE; NONHUMAN; PH; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRODUCT RECOVERY; ROOM TEMPERATURE; SILVER STAINING; WESTERN BLOTTING; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIGENS, PROTOZOAN; BUFFERS; DRUG STORAGE; HUMANS; MALARIA VACCINES; MEMBRANE PROTEINS; PROTOZOAN PROTEINS; QUALITY CONTROL; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84355161418     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.025     Document Type: Article

References (33)

1. Glenny A.T., Pope C.G., Waddington H., Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926, 3(29):8-45.
2. World Health Organization Manual for the production and control of vaccines-tetanus toxoid 1977, WHO, Geneva.
3. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(3):155-172.
4. Gupta R.K., Rost B.E. Aluminum compounds as vaccine adjuvants. Vaccine adjuvant 2000, Humana Press, pp. 65-89.
5. Hem S.L., HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Exp Rev Vaccines 2007, 6(5):685-698.
6. Lindblad E.B. Aluminum compounds for use in vaccines. Immunol Cell Biol 2004, 82:497-505.
7. Iyer S., Robinett R.S.R., HogenEsch H., Hem S.L. Mechanism of adsorption of hepatitis B surface antigen by aluminium hydroxide adjuvant. Vaccine 2004, 22:1475-1479.
8. Al-Shakhshir R.H., Regnier F.E., White J.L., Hem S.L. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995, 13:41-44.
9. Rinella J.V., White J.L., Hem S.L. Effect of anions on model aluminium-adjuvant-containing vaccines. J Colloid Interface Sci 1995, 172:121-130.
10. Rinella J.V., White J.L., Hem S.L. Effect of pH on the elution of model antigens from aluminium-containing adjuvants. J Colloid Interface Sci 1998, 205:161-165.
11. Rinella J.V., White J.L., Hem S.L. Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine 1996, 14(4):298-300.
12. Chang M.F., White J.L., Nail S.L., Hem S.L. Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant. PDA J Pharm Sci Technol 1997, 51:25-29.
13. Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991, 9(3):201-203.
14. Iyer S., HogenEsch H., Hem S.L. Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm Dev Technol 2003, 8(1):81-86.
15. Shi Y., HogenEsch H., Hem S.L. Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine 2001, 20(1-2):80-85.
16. Heimlich J.M., Regnier F.E., White J.L., Hem S.L. The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial fluid. Vaccine 1999, 17:2873-2881.
17. Chang M.F., Shi Y., Nail S.L., HogenEsch H., Adams S.B., White J.L., et al. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 2001, 19:2884-2889.
18. Flarend R.E., Hem S.L., White J.L., Elmore D., Suckow M.A., Rudy A.C., et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 1997, 15:1314-1318.
19. Iyera S., HogenEschb H., Hem S.L. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 2003, 21:1219-1223.
20. Seeber S.J., White J.L., Hem S.L. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J Parenter Sci Technol 1991, 45:156-160.
21. Aebig J.A., Mullen G.E., Dobrescu G., Rausch K., Lambert L., Miles A.P., et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 2007, 323(2):139-146.
22. Rapoza R.J., Horbett T.A. Changes in the SDS elutability of fibrinogen adsorbed from plasma to polymers. J Biomater Sci Polym Ed 1989, 1(2):99-110.
23. Rapoza R.J., Horbett T.A. Postadsorptive transitions in fibrinogen: influence of polymer properties. J Biomed Mater Res 1990, 24(10):1263-1287.
24. Bohnert J.L., Horbett T.A. Changes in adsorbed fibrinogen and albumin interactions with polymers indicated by decreases in detergent elutability. J Colloid Interface Sci 1986, 111:363-377.
25. Rapoza R.J., Horbett T.A. The effects of concentration and adsorption time on the elutability of adsorbed proteins in surfactant solutions of varying structures and concentrations. J Colloid Interface Sci 1990, 136:480-493.
26. Krisdhasima V., Vinaraphong P., McGuire J., Adsorption Kinetics Elutability of α-lactalbumin, β-casein β-lactoglobulin, and bovine serum albumin at hydrophobic and hydrophilic interfaces. J Colloid Interface Sci 1993, 161:325-334.
27. Elwing H., Golander C. Protein and detergent interaction phenomena on solid surfaces with gradients in chemical composition. Adv Colloid Interface Sci 1990, 32:317-339.
28. Chinn J., Posso S.E., Horbett T.A., Ratner B.D. Postadsorptive transitions in fibrinogen adsorbed to polyurethanes: changes in antibody binding and sodium dodecyl sulfate elutability. J Biomed Mater Res 1992, 26(6):757-778.
29. Rinella J.V., Workman R.F., Hermodson M.A., White J.L., Hem S.L. Elutability of proteins from aluminium-containing vaccine adjuvants by treatment with surfactants. J Colloid Interface Sci 1998, 197:48-56.
30. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002, 70(12):6948-6960.
31. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005, 73:3677-3685.
32. ® ISA 720 and stabilized with glycine. Vaccine 2011, 29(20):3640-3645.
33. Miura K., Orcutt A.C., Muratova O.V., Miller L.H., Saul A., Long C.A. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 2008, 26(2):193-200.